AstraZeneca is primarily a publicly traded company with ownership concentrated in institutional investors. It was formed in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. The major shareholders as of early 2025 include large institutional investors such as Vanguard Group Inc., BlackRock Inc., and Capital Research Global Investors, which together hold a significant majority (often exceeding 70-80%) of the company's shares. The company is listed on the London Stock Exchange, Nasdaq Stockholm, and the American Nasdaq. Thus, no single individual or entity "owns" AstraZeneca; instead, ownership is distributed among public and institutional shareholders globally.
